Hainan Shuangcheng Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jianming Li

Chief executive officer

CN¥828.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	4.8yrs
CEO ownership	0.4%
Management average tenure	1.8yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

Subdued Growth No Barrier To Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Price

Aug 03

Getting In Cheap On Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) Is Unlikely

Apr 15

CEO

Jianming Li (68 yo)

4.8yrs

Tenure

CN¥828,000

Compensation

Mr. Jianming Li serves as an General Manager of Hainan Shuangcheng Pharmaceutical Co., Ltd. and serves as its Non-Independent director since January 16, 2020. He served as Executive Deputy General Manager...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jianming Li	GM & Non-Independent Director	no data	CN¥828.00k	0.42% CN¥ 42.9m
Xuguang Wang	Financial Director & Chief Financial Officer	14yrs	CN¥380.00k	0.17% CN¥ 17.1m
Xiaofeng Yu	Deputy GM & Secretary of the Board	14yrs	CN¥380.00k	0.16% CN¥ 16.4m
Jianlin Yuan	Deputy General Manager	no data	CN¥494.80k	0.15% CN¥ 15.1m
Zhong Yao	Deputy General Manager	1.8yrs	CN¥833.20k	0.078% CN¥ 7.9m
Shiying Wang	Deputy General Manager	1.8yrs	CN¥367.40k	0.030% CN¥ 3.0m
Yixiang Ai	Deputy General Manager	1.8yrs	CN¥362.80k	0.017% CN¥ 1.8m
Haiyan Li	Deputy General Manager	1.8yrs	CN¥332.60k	0.013% CN¥ 1.3m
Rui Wang	Deputy General Manager	1.8yrs	CN¥332.20k	0.015% CN¥ 1.5m
Yuan Li	Deputy General Manager	1.8yrs	CN¥362.30k	0.016% CN¥ 1.6m
Yun Zhou	Accounting Supervisor	no data	no data	no data

1.8yrs

Average Tenure

45yo

Average Age

Experienced Management: 002693's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jianming Li	GM & Non-Independent Director	4.8yrs	CN¥828.00k	0.42% CN¥ 42.9m
Chengdong Wang	Chairman	14yrs	no data	0.51% CN¥ 51.7m
Yingpu Wang	Vice Chairman	14yrs	CN¥796.00k	15.58% CN¥ 1.6b
Bin Fu	Non-Employee Supervisor	14yrs	no data	no data
Jing Bai	Vice Chairman	2.8yrs	no data	no data
Hongyu Wang	Chairman of the Supervisory Board	7.8yrs	no data	no data
Jianwei Li	Independent Director	1.8yrs	CN¥60.00k	no data
Jianhua Xiao	Independent Director	1.8yrs	CN¥60.00k	no data
Ying Chen	Non-Employee Supervisor	1.8yrs	no data	no data

4.8yrs

Average Tenure

48yo

Average Age

Experienced Board: 002693's board of directors are considered experienced (4.8 years average tenure).

Hainan Shuangcheng Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 06, 2022

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Elects Bai Jing as Non-Independent Director

Recent updates

Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.024 loss in 3Q 2023)

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

New major risk - Revenue and earnings growth

Subdued Growth No Barrier To Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Price

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: CN¥0.021 loss per share (vs CN¥0.011 profit in 1Q 2023)

Getting In Cheap On Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) Is Unlikely

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Share price stability

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.006 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.006 loss in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.05 loss in FY 2021)

Less than half of directors are independent

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments

Third quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.024 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.023 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.008 loss in 1Q 2021)

Hainan Shuangcheng Pharmaceuticals Co., Ltd., Annual General Meeting, May 06, 2022

Full year 2021 earnings released: CN¥0.05 loss per share (vs CN¥0.13 loss in FY 2020)

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Elects Bai Jing as Non-Independent Director

Third quarter 2021 earnings released: CN¥0.94 loss per share (vs CN¥0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.011 (vs CN¥0.036 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.13 loss per share (vs CN¥0.06 profit in FY 2019)

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 21, 2021

New 90-day low: CN¥3.69

New 90-day low: CN¥3.91

New 90-day low: CN¥4.45

Third quarter earnings released

New 90-day low: CN¥4.84

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥5.00

Hainan Shuangcheng Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age